3 unknown. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Unknown 3 |
Follow Genova Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Novaferon in Non-hospitalized Adult Patients With Mild COVID-19 Novaferon, Placebo - Covid19 | Phase 3 | Unknown | Genova Inc. | 222 | 2021-10-28 | 2022-03-03 |
| Phase 3 Inhaled Novaferon Study in Hospitalized Patients With Moderate to Severe COVID-19 Novaferon, Placebo - Covid19 | Phase 3 | Unknown | Genova Inc. | 914 | 2021-06-10 | 2022-06-03 |
| Novaferon for COVID-19 Treatment Trial (NCTT-005) Novaferon, Placebo - Covid19 | Phase 3 | Unknown | Genova Inc. | 385 | 2021-03-25 | 2022-01-28 |
COVID-19 (3)
recombinant interferon alpha 2b-like protein (3) · Standard of Care (1)
Japan (2) · Argentina (1) · Brazil (1) · Canada (1) · Chile (1) · Colombia (1) · Indonesia (1) · Kenya (1) · Malaysia (1) · Peru (1) · South Africa (1) · Turkey (Türkiye) (1) · Ukraine (1)